Drug Profile
Vamorolone - Santhera Pharmaceuticals
Alternative Names: AGAMREE; VB-15; VBP-15Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator ReveraGen BioPharma
- Developer ReveraGen BioPharma; Santhera Pharmaceuticals; Sperogenix Therapeutics
- Class Anti-inflammatories; Antianaemics; Antiasthmatics; Antifibrotics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duchenne muscular dystrophy
- Preclinical Unspecified
- Discontinued Amyotrophic lateral sclerosis; Asthma; Brain cancer; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia; Spinal muscular atrophy
Most Recent Events
- 27 Mar 2024 Clinical trials in Duchenne muscular dystrophy (In volunteers) in China (PO) prior to March 2024
- 27 Mar 2024 Preregistration for Duchenne muscular dystrophy (In Children, In adolescents, In adults, In the elderly) in China (PO) prior to March 2024
- 27 Mar 2024 The Center for Drug Evaluation (CDE) of the Chinese drug authority NMPA grants priority review for vamorolone for Duchenne muscular dystrophy (In Children, In adolescents, In adults, In the elderly)